The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
 
Xiaolin Zhu
Employment - Exelixis (I)
 
Daniel J Vis
No Relationships to Disclose
 
Martin Sjöström
No Relationships to Disclose
 
Raunak Shrestha
No Relationships to Disclose
 
Jeroen Kneppers
No Relationships to Disclose
 
Tessa Severson
No Relationships to Disclose
 
Yanyun Zhu
No Relationships to Disclose
 
Haolong Li
No Relationships to Disclose
 
Tatyanah Farsh
No Relationships to Disclose
 
Meng Zhang
No Relationships to Disclose
 
Arian Lundberg
No Relationships to Disclose
 
Thaidy Moreno Rodriguez
No Relationships to Disclose
 
Adam Foye
No Relationships to Disclose
 
Andre M. Bergman
No Relationships to Disclose
 
Wilbert Zwart
Research Funding - Astellas Pharma
 
David Alan Quigley
No Relationships to Disclose
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
Eric J. Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Fortis; Janssen Oncology; Teon Therapeutics
 
Michiel Simon Van Der Heijden
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Felix Y Feng
Stock and Other Ownership Interests - Artera; Bluestar Genomics; Serimmune
Consulting or Advisory Role - Artera; Astellas Pharma; Bayer; BlueStar Genomics; Bristol Myers Squibb; Bristol Myers Squibb (BMS); Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; POINT Biopharma; Roivant; SerImmune; Tempus; Varian Medical Systems
Research Funding - Zenith Epigenetics